CTL019: Additional Phase I/IIa data

Data from 30 pediatric and adult patients with relapsed or refractory ALL in an open-label, U.S. Phase I/IIa trial showed that CTL019 led to complete remission in 27 patients (90%) at 1 month post-infusion. The overall survival (OS) rate was 78% and the 6-month event-free survival (EFS) rate was 67%. All patients had cytokine release syndrome. Patients with severe cytokine release syndrome were effectively treated with Actemra tocilizumab from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland). Data were published in The New England Journal of Medicine. Previously reported data from 22 pediatric patients in the trial showed that CTL019 led to complete remission in 19 patients (86%) (see BioCentury, Dec. 23, 2013). ...